Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab ± chemotherapy as first-line treatment for advanced NSCLC with COPD
ChiCTR2600121738Phase 2Not yet recruiting
- Sponsor
- Jinling Hospital
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab in non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Jinling Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2600121738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121738.